Literature DB >> 7844371

Phagocytosis of Streptococcus pneumoniae measured in vitro and in vivo in a rat model of carbon tetrachloride-induced liver cirrhosis.

M J Gentry1, M U Snitily, L C Preheim.   

Abstract

Both humans and rats with liver cirrhosis have increased morbidity and mortality from pneumococcal pneumonia. By use of a rat model of carbon tetrachloride-induced liver cirrhosis, uptake of fluorochrome-labeled Streptococcus pneumoniae by polymorphonuclear leukocytes (PMNL) and alveolar macrophages (AM) was examined by flow cytometry. Peripheral blood PMNL from cirrhotic rats showed no defect in phagocytic or bactericidal capacity for type 10A S. pneumoniae in vitro. However, in vivo, fewer type 3 S. pneumoniae were engulfed by PMNL in the lungs of cirrhotic rats with a concomitant increase in the number of organisms taken up by their AM in comparison with controls. These studies indicate the importance of using more relevant in vivo methodologies for assessing bacterial phagocytosis. In addition, the reduction in uptake of type 3 pneumococci by PMNL within the microenvironment of the cirrhotic rat lung could help to explain the increased susceptibility of cirrhotic rats to pneumococcal pneumonia.

Entities:  

Mesh:

Year:  1995        PMID: 7844371     DOI: 10.1093/infdis/171.2.350

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  12 in total

1.  Pneumolysin-induced complement depletion during experimental pneumococcal bacteremia.

Authors:  R B Alcantara; L C Preheim; M J Gentry-Nielsen
Journal:  Infect Immun       Date:  2001-06       Impact factor: 3.441

2.  Comparison of a classical phagocytosis assay and a flow cytometry assay for assessment of the phagocytic capacity of sera from adults vaccinated with a pneumococcal conjugate vaccine.

Authors:  W T Jansen; M Väkeväinen-Anttila; H Käyhty; M Nahm; N Bakker; J Verhoef; H Snippe; A F Verheul
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

3.  In vitro and in vivo interactions of Haemophilus ducreyi with host phagocytes.

Authors:  Hinda J Ahmed; Catharina Johansson; Liselott A Svensson; Karin Ahlman; Margareta Verdrengh; Teresa Lagergård
Journal:  Infect Immun       Date:  2002-02       Impact factor: 3.441

Review 4.  Alcohol abuse and Streptococcus pneumoniae infections: consideration of virulence factors and impaired immune responses.

Authors:  Minny Bhatty; Stephen B Pruett; Edwin Swiatlo; Bindu Nanduri
Journal:  Alcohol       Date:  2011-09       Impact factor: 2.405

5.  The dual role of interferon-gamma in experimental Staphylococcus aureus septicaemia versus arthritis.

Authors:  Y X Zhao; I M Nilsson; A Tarkowski
Journal:  Immunology       Date:  1998-01       Impact factor: 7.397

6.  Role of neutrophil leukocytes in cutaneous infection caused by Staphylococcus aureus.

Authors:  L Mölne; M Verdrengh; A Tarkowski
Journal:  Infect Immun       Date:  2000-11       Impact factor: 3.441

Review 7.  Animal models of Streptococcus pneumoniae disease.

Authors:  Damiana Chiavolini; Gianni Pozzi; Susanna Ricci
Journal:  Clin Microbiol Rev       Date:  2008-10       Impact factor: 26.132

8.  Repetitive organic dust exposure in vitro impairs macrophage differentiation and function.

Authors:  Jill A Poole; Neil E Alexis; Conrad Parks; Amy K MacInnes; Martha J Gentry-Nielsen; Paul D Fey; Lennart Larsson; Diane Allen-Gipson; Susanna G Von Essen; Debra J Romberger
Journal:  J Allergy Clin Immunol       Date:  2008-06-27       Impact factor: 10.793

9.  High mortality of pneumonia in cirrhotic patients with ascites.

Authors:  Tsung-Hsing Hung; Chih-Wei Tseng; Yu-Hsi Hsieh; Kuo-Chih Tseng; Chih-Chun Tsai; Chen-Chi Tsai
Journal:  BMC Gastroenterol       Date:  2013-02-07       Impact factor: 3.067

10.  Cirrhosis-induced defects in innate pulmonary defenses against Streptococcus pneumoniae.

Authors:  Katie L Propst-Graham; Laurel C Preheim; Elizabeth A Vander Top; Mary U Snitily; Martha J Gentry-Nielsen
Journal:  BMC Microbiol       Date:  2007-10-23       Impact factor: 3.605

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.